Compass Pathways Plc (CMPS NASDAQ) stock market data APIs
$7.5698
0.19(2.5%)
as of February 17, 2026
Try our APIs with
free plan!
Compass Pathways Plc Financial Data Overview
Price chart is built with
Anychart
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Prev. Close
7.5698
Open
7.7602
High
8.7298
Low
7.2406
52 wk Range
2.25-8.7951
Market Cap
733 M
Shares Outstanding
96 017 K
EPS
-0.3836
Beta
1.925
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Compass Pathways Plc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Compass Pathways Plc data using free add-ons & libraries
Get Compass Pathways Plc Fundamental Data
Compass Pathways Plc Fundamental data includes:
- Net Revenue:
- EBITDA: -154 376 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-10-30
- EPS/Forecast: -0.3955
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Compass Pathways Plc News
New
Why Did Compass Pathways Stock Rocket Higher Today?
It's been a long road for Compass Pathways(NASDAQ: CMPS) to prove that its treatment using psilocybin therapy for treatment-resistant depression (TRD) can be successful. It was back in 2018 when the c...
Why Did Compass Pathways Stock Rocket Higher Today?
Key Points Phase 3 clinical trial data has been a success. COMP360 is the first traditional psychedelic to consistently deliver a highly statistically significant outcome. Results included maintaini...
Biggest stock movers Tuesday: ZIM, CMPS, and more
[Technical Price Chart Data Analysis Showing 2020 Corona Virus Covid-19 Stock Market Crash] Stock futures dipped Tuesday morning amid a holiday-shortened trading week, spotlighting key economic data a...
Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials
LONDON & NEW YORK, February 16, 2026--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced tha...
Get Compass Pathways Plc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
